Industry News

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

05/10/2021

Excerpt from the Press Release: ZUG, Switzerland, CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Nkarta, Inc. (NASDAQ: NKTX), a biopharmaceutical company developing engineered NK cell therapies to treat cancer, today announced a…

Read More

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

05/07/2021

Excerpt from the Press Release: BOSTON, April 29, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial, which…

Read More

Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer

05/06/2021

Excerpt from the Press Release: MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer, today announced updated results from its Phase 1/2 pilot trial of GC4419,…

Read More

LIPAC Oncology Announces Successful Type B Meeting with the U.S. FDA for the Study of LiPax for Non-Muscle Invasive Bladder Cancer

05/05/2021

Excerpt from the Press Release: MENLO PARK, Calif., April 29, 2021 /PRNewswire/ — LIPAC Oncology LLC today announced the conclusion of a successful Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss Phase 2b/3 clinical trials of LiPax in patients with low-grade highly recurrent non-muscle invasive bladder cancer (NMIBC). The feedback from the FDA provides…

Read More

Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board

05/04/2021

Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., April 29, 2021 (GLOBE NEWSWIRE) — Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today three key additions to its Board of Directors: Dr. David Zaccardelli, Ms. Natalie McDonald, and Mr. Gary Sender. The company also announced the transition of Robert…

Read More

AI System Detects Frequently Overlooked Fractures on X-ray

05/03/2021

Excerpt from the Article: Identifying these easily missed breaks can save patients from future negative complications or loss of function. A significant number of the most common type of wrist fracture go undetected on X-ray images, setting patients up for potential problems downstream. But, a new artificial intelligence (AI)-based automated system can improve detection rates.…

Read More

Good Isn’t Good Enough: Moderna Continues Efforts to Improve COVID-19 Vaccine

05/03/2021

Excerpt from the Article: Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., isn’t resting on its accomplishments but is instead working to scale up production further and improve on its vaccine. One of the downsides of the vaccine initially was its cold-storage requirements. It is approved for storage at between 36…

Read More

Cancer Researchers Receive Grant to Study Indolent Neuroblastoma

04/30/2021

Excerpt from the Press Release: PHILADELPHIA, April 20, 2021 /PRNewswire/ — A trans-Atlantic collaborative group of researchers led by Children’s Hospital of Philadelphia (CHOP) has received approximately $680,000 from a group of research charities led by Solving Kids’ Cancer UK to study slowly progressive, or “indolent,” neuroblastoma, which does not respond to chemotherapy and lacks other treatment options. The grant will fund…

Read More

Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax’s CpG 1018™ Adjuvant

04/30/2021

Excerpt from the Press Release: EMERYVILLE, Calif., April 21, 2021 /PRNewswire/ — DYNAVAX TECHNOLOGIES CORPORATION (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced Valneva SE has initiated a pivotal Phase 3 clinical trial for its inactivated, COVID-19 vaccine candidate, VLA2001, using Dynavax’s CpG 1018 adjuvant.  The Phase 3 trial “Cov-Compare”, (VLA2001-301), will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against…

Read More

Clinical Trial Restart Resource Toolkit

04/29/2021

Clinical Trials Ontario has released a Clinical Trial Restart Toolkit! “This toolkit provides a collection of best practices, considerations, and resources for clinical trial conduct in the face of the COVID-19 pandemic. The aim of this toolkit is to provide guidance for sites and sponsors that are looking to restart clinical trials during a pandemic.…

Read More